Abstract: Fat grafting is increasingly popular and is becoming a common practice in plastic surgery for postmastectomy breast reconstruction and aesthetic breast augmentation; however, concerns over the oncologic safety remains a controversial and hot topic among scientists and surgeons. Basic science and laboratory research repeatedly show a potentially dangerous effect of adipose-derived stem cells on breast cancer cells; however, clinical research, although limited, continually fails to show an increase in breast cancer recurrence after breast fat grafting, with the exception of 1 small study on a subset patient population with intraepithelial neoplasm of the breast. The aim of this review is to summarize the recent conflicting basic science and clinical data to better understand the safety of breast fat grafting from an oncological perspective.
I
n 1987, the American Society of Plastic Surgeons (ASPS) banned autologous fat grafting to breasts primarily over concerns of future cancer surveillance in the setting of fat necrosis, and secondarily because of inconsistency in graft retention. 1 In 2007, the ASPS established a task force to reevaluate the potential hazards and benefits of breast fat grafting concluding current radiographic technology can distinguish grafted fat from potentially dangerous lesions with acceptable risk and that autologous fat grafting to the breasts may be useful and safe, but lacks standardization. 2 In 2009, the ASPS lifted the ban on autologous fat grafting owing to lack of evidence; however, the ASPS Fat Graft Task Force stated that surgeons should exercise "caution when considering fat grafting procedure in patients at high risk for breast cancer". 3 Although breast cancer remains the most common cancer in women, fat grafting has become increasingly more popular and common in plastic surgery for postmastectomy breast reconstruction and also aesthetic breast augmentation. 4 Fat grafting offers autologous tissue transfer without microsurgical expertise or resources, can be performed in the outpatient setting with fast patient recovery, and has minimal donor site morbidity. Although the technique of fat grafting has been widely studied and shown to have an acceptable minor complication risk, with the recent discovery of adipose-derived stem cells (ASCs) in fat tissue, the concern for oncologic recurrence risk remains a highly debated and controversial topic among surgeons and scientists. [5] [6] [7] The ASCs are a subtype of mesenchymal stem cells (MSCs) and exhibit common characteristics of MSCs, such as the capacity to differentiate into different cell types (eg, osteocytes, chondrocytes), and secretion of growth factors. 5 , and increased tumor growth and metastasis using in vivo xenograft models.
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The aim of this review is to evaluate the recent data on clinical breast cancer recurrence after breast fat grafting and discuss it in the setting of the contradicting recent basic science studies that repeatedly demonstrate potentially dangerous effects of ASCs on breast cancer cells using both in vitro and in vivo xenograft models. Our intention is to shed light on the conundrum of the oncologic safety of breast fat grafting.
LITERATURE REVIEW
We carried out a literature search in PubMed and Google Scholar databases using "fat graft" or "fat grafting" or "lipomodelling" or "lipofilling" or "autologous fat" and "breast cancer" as search terms. We limited this review to recent literature and searched all the papers published from January 2010 to December 2014 (Fig. 1) . In total, 16 clinical and 9 basic science studies were used.
Inclusion Criteria
Original articles pertaining to clinical studies of human patients undergoing fat grafting to the breast with mention of breast cancer recurrence were eligible for inclusion in this review. Basic science literature studying the interaction of ASCs and breast cancer cells, as well as studies using xenograft models for coinjection of ASCs and breast cancer cells, were also eligible.
Exclusion Criteria
Duplicate studies and studies with less than 25 patients and/or less than 12 months follow-up after breast fat grafting were excluded. In addition studies, without original data, including reviews, were excluded.
THE INTERACTION OF ASCS AND BREAST CANCER CELLS
As the controversy over the safety of breast fat grafting after breast cancer grows, many scientists and surgeons have turned to the laboratory to get a better understanding of ASCs and its interaction with breast cancer cells. Studies performed using different experimental models come to the common conclusion that MSCs, documented that 2 distinct populations of progenitor cells isolated from human adipose tissue play a role in increased cancer recurrence. In these studies, endothelial progenitor cells generated mature endothelial cells and capillaries within the tumor but their cancer-promoting effect in the breast was limited in the absence of ASCs, which supported new vessel formation and were more efficient than endothelial progenitor cells in promoting local tumor growth. Therefore, they concluded that ASCs and endothelial progenitor cells cooperate in driving progression and metastatic spread of breast cancer. 14 Similarly, Rowan et al 11 discovered increased migration of breast cancer cells when cocultured with ASCs. More interestingly, they found increased micrometastasis in first pass organs, specifically the liver, lung and spleen, in a murine xenograft model suggesting a role of ASCs in angiogenesis and increased metastatic potential of breast cancer cells (Fig. 2) .
Another theory on ASC-breast cancer cell interaction was direct intercellular contact between ASCs and breast cancer cells leading to morphological changes and increased expression of transcriptional genes for typical malignancy markers. 10 Eterno et al 8 studied the interaction between ASCs and primary breast cancer isolates from patients. They found a direct correlation between c-Met expression in breast cancer cells and susceptibility to tumorigenesis promoting effects of ASCs. The ASCs associated with increased tumorigenesis also showed increased expression of hepatocyte growth factor. Additionally, human donors with increased expression of c-Met on breast cancer cells developed cancer recurrence after fat grafting (Fig. 3) . The authors concluded that a master role for hepatocyte growth factor/c-Met crosstalk in mediating a tumorigenic role of ASCs in breast cancer must exist.
Given the large volume of preclinical data available, of which only a small sample is reviewed above, adipose tissue is now considered not only an energy storage depot, but also an active endocrine tissue that interacts closely with the surrounding tissues. This is further supported by a study by Sturtz et al 16 that revealed an upregulated expression of genes involved in inflammation, proliferation, invasion, and migration in human adipose tissue adjacent to breast cancer, concluding adipose tissue is not inert, but plays an active fluent role in tumorigenesis. Therefore, the possible role of adipose tissue in breast tumorigenesis should be taken into consideration when planning fat grafting in a patient at increased risk for the development of breast cancer.
THE CLINICAL RISK OF FAT GRAFTING
In total, 16 clinical studies including 2100 patients were reviewed ( Table 1 ). The overall rate of local breast cancer recurrence after fat grafting was 2.2% with recurrence noted in 47 patients. Various studies encompassed a diverse patient population undergoing a wide range of surgical procedures from fat grafting alone to fat grafting after autologous flap and/or implant placement. Some subjects underwent multiple fat grafting procedures as well. Breast cancer recurrence was limited to locoregional events; however, distant metastasis is discussed in the comments sections of Table 1 where applicable. In summary, 6 clinical studies demonstrate no breast cancer recurrences in a number of patients ranging from 28 to 151 with a minimum follow-up of 12 months. 21, 23, 25, 29, 31, 32 Three published prospective trials including 158, 67, and 59 patients found breast cancer recurrence rates were 0.6%, 0.0%, and 5.1% with 1, 0 , and 3 patients, respectively, discovered to have breast cancer recurrence at an average follow-up of 18, 12, and 34 months. 19, 21, 30 Two clinical studies, including 60 and 137 patients, after a relatively long followup, with an average of at least 90 months, showed recurrence rates of 3.3% and 3.6%, respectively. 17, 28 Other retrospective analyses with shorter average follow up periods (<50 months) showed recurrence rates of 2.2%, 3.2%, and 3.1%. 20, 24, 26 The largest patient series was published by Petit et al 18 in 2011. This was a multicenter analysis of 513 patients undergoing breast fat grafting after mastectomy or breast conserving therapy with invasive carcinoma and/or cancer in situ revealing a local recurrence rate of 2.4% (1.5% per year) and distant recurrence of 3.1% (1.9% per year). 18 The following year, 321 consecutive patients were analyzed against a 1:2 match cohort with similar characteristics with local recurrence in 8 (2.5%) compared to 19 (3.0%) in the cohort control. However, when analysis was limited to a subset of 37 patients with intraepithelial neoplasms, 4 local recurrences existed (10.8% local recurrence rate) versus none in the cohort, a significant difference. 22 The initial findings prompted the team to perform a matched cohort study of 59 patients with intraepithelial neoplasms undergoing breast fat grafting compared to 118 matched patients not undergoing breast fat grafting, revealing an 18% 5-year cumulative risk of local recurrence in the breast fat grafting group compared to 3% in the cohort control (P = 0.02). 27 In summary, the overall local recurrence rate of 2.2% in patients undergoing breast fat grafting was comparable to the published breast cancer recurrence rates (5.2-10.6%) in patients without breast fat grafting after breast cancer surgery. [33] [34] [35] [36] [37] However, fat grafting in the presence of known ductal or lobular intraepithelial neoplasms has up to an 18% 5-year local recurrence rate.
CURRENT FAT GRAFTING REGULATIONS
In 2011, a joint task force of the American Society for Aesthetic Plastic Surgery and the ASPS was created in response to raising concerns relating to stem cell therapies in aesthetic plastic surgery. The task force recommended caution toward "stem cell breast augmentation" (as advertised), considering the lack of consistency in how these procedures are performed and how stem cells are incorporated into the procedure. The task force extended this caution to instructional courses which are designed to teach methods of stem cell extraction for aesthetic procedures, and specialized equipment being marketed to physicians for use in "stem cell procedures."
The Task Force also conducted a systematic review of the peer reviewed medical literature on fat grafting and stated that the marketing and promotion of stem cell procedures in aesthetic surgery is not adequately supported by clinical evidence and recommended that, until further evidence is available, stem cell therapies in aesthetic and reconstructive surgery should be conducted under Institutional Review Board approval. In December 2014, the US Department of Health and Human Services, Division of Food and Drug Administration published a draft guidance for human cell, tissues, and cellular and tissue-based products (HCT/P) from adipose tissue: regulatory considerations, labeled 21 CFR. 39 According to this publication, adipose tissue must meet the following requirements for clinical use: (1) minimal manipulation; (2) homologous use only; (3) no combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition does not raise new clinical safety concerns; (4) adipose tissue cannot have a systemic effect and be dependent upon the metabolic activity of living cells for its primary function, unless for autologous use, allogeneic use in a firstdegree or second-degree blood relative, or reproductive use. It is also stated that HCT/P from adipose tissue for nonimplant augmentation would not be consistent with the basic function of breast tissue and generally be considered a nonhomologous use. However, when HCT/ Ps are removed from an individual and implanted in the same individual in the same surgical procedure, and as long as HCT/P does not undergo processing beyond rinsing, cleansing, or sizing, they are not required to comply with requirements in 21 CFR Part 1271. Despite recognizing autologous fat grafting to the breast as a nonhomologous use and therefore not compliant with its regulations, the Food and Drug Administration made an exception for certain surgical techniques that allows intraoperative harvest and injection, including the Coleman technique which utilizes intraoperative centrifuge.
CONCLUSIONS AND FUTURE DIRECTIONS
Currently, the basic science and clinical studies provide contradictory evidence with regard to the safety of breast fat grafting. 40, 41 Even when using cellassisted lipotransfer, described by Yoshimura et al, [42] [43] [44] which combines processed stromal vascular fraction with adipose lipoaspirate to create an ASC-rich fat graft, the ASC concentration is much smaller than ex vivo expansion techniques used in the basic science studies. This may explain why most clinical studies looking at recurrence rates of breast cancer after fat grafting show no difference than nonfat-grafted breast cancer patients. With the exception of Petit et al who has shown there may be an increased risk of recurrence in patients with intraepithelial neoplasms, there are no reports on increased risk of breast cancer recurrence associated with fat grafting to the breast.
At this point, there is not enough good data to make a definitive claim about the oncologic safety of breast fat grafting in patients. The best studies thus far suggest there is no increased risk of cancer associated with fat grafting, but these are limited by lack of standardization of surgical technique and fat harvest method, inadequate controls, retrospective analysis, and insufficient long-term follow-up. Although a prospective randomized trial is desirable, this will likely not occur. More well-controlled cohort studies with sufficiently long follow-up of a minimum of 120 months demonstrating similar findings that there is no increased cancer risk associated with fat grafting will provide clinicians and patients peace of mind when fat grafting to breast. Currently, patients with known intraepithelial tumors should be cautioned that there are studies to suggest increased recurrence rates associated with fat grafting. This conversation should be included in the informed consent of all patients considering fat grafting as part of their breast procedures.
Basic science studies often used banked breast cancer cell lines, which tend to be more durable and mutated compared to residual breast cancer cells after surgery in the average patient. Thus, basic science studies can be made more clinically relatable by using clinical breast cancer samples and ASCs harvested from the same patient to provide a more accurate clinical correlation.
Although there is no denying the aesthetic advantages of breast fat grafting especially in conjunction with implant or Brava system tissue expansion, surgeons should be sure to provide appropriate informed consent when performing breast fat grafting on breast cancer patients until more studies with longer follow-up are completed. 45, 46 We also believe surgeons performing breast fat grafting for aesthetic augmentation in young patients with a strong family history of breast cancer must inform their patients of the limited data available on cancer rates in highrisk patients after breast fat grafting to healthy tissue. 
